Researchers conducted a randomized controlled trial designed to determine the effect of Twin Precision Treatment (TPT) technology versus standard care (SC) on the course of A1C remission and type 2 diabetes at 90 day intervals. The TPT intervention uses the Whole-Body Digital Twin platform, with AI and the Internet of Things, to integrate multi-dimensional data to provide accurate advice on nutrition, sleep, activity and breathing via the TPT app and coaches.
The average initial age, the duration of diabetes and the A1C obtained in 319 patients were respectively 45 years (± 9.7 years), 3.9 years (± 2.9 years) and 9% (± 1.9 %). Interim analysis of 262 patients (TPT n=199; SC n=63) who reached 180 days showed that 94.9% (189/199) of TPT patients achieved A1C less than 6.5% without medication or with metformin only; 83.9% (167/199) achieved diabetes remission according to ADA Criteria. The nine patients on insulin stopped insulin before 90 days. The TPT intervention in patients with type 2 diabetes resulted in a significant reduction in A1C, diabetes remission (~84%), and improvement in several metabolic parameters at six months.
“Our results demonstrate the potential of Whole Body Digital Twin technology to change conventional, medication-based type 2 diabetes management to achieve type 2 diabetes remission with a drug-free life,” said Paramesh Chamanna, MD, lead author of the study. “The impact of the program on patient satisfaction, quality of life and total cost of care is substantial and holds great promise for large populations with metabolic diseases worldwide.”
Whole Body Digital Twin is a predictive model that provides individualized nutrition, sleep, activity and breathing guidance to patients and their healthcare providers, with the potential to help reverse diabetes and disease metabolic. The technology was built from thousands of data points collected daily via non-invasive wearable sensors, providing a personalized representation of each individual’s unique metabolism.
The authors note that future long-term studies are needed to substantiate these early findings.
Details of the research presentation:
For more information or to request an interview, please contact the ADA The media team of the Scientific Sessions at [email protected].
About ADA Scientific Sessions
The ADA 82n/a Scientific Sessions, the world’s largest scientific meeting focused on diabetes research, prevention and care, will be a hybrid event taking place June 3-7, 2022 at the Ernest N. Morial Convention Center in New Orleans, LA. Leading doctors, scientists and healthcare professionals from around the world will unveil cutting-edge research, treatment recommendations and advances towards a cure for diabetes. We look forward to getting back to participating in person and safely networking with colleagues while listening to the latest scientific advances and groundbreaking research presentations. Learn more and register at scientificsessions.diabetes.org and join the Science Sessions conversation on social media using #ADA2022.
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve of the diabetes epidemic and help people with diabetes thrive. For 81 years, the ADA led discovery and research to treat, manage and prevent diabetes while working tirelessly for a cure. Through advocacy, program development and education, we aim to improve the quality of life for the more than 133 million Americans with diabetes or prediabetes. Diabetes brought us together. What we do next will make us connected for life. To find out more or to get involved, go to diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (American Diabetes Association), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
Contact: Daisy Diaz, 504-670-4902
SOURCE American Diabetes Association